Video+

John Wilding gives an overview of the SURPASS findings to date, and discusses their importance and how tirzepatide may be used in the clinic.

Michelle Welch discusses the positive glycemic and weight loss findings for tirzepatide versus placebo in people with insulin-dependent type 2 diabetes in SURPASS-5.

Deborah Wexler discusses the findings from GRADE, a head-to-head study comparing glimepiride, sitagliptin, insulin glargine, and liraglutide when used in combination with metformin for the treatment of type 2 diabetes.

Juan Pablo Frías discusses whether the findings of SUSTAIN-FORTE will justify an increase in the approved maximum dose of semaglutide for people with type 2 diabetes.

Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide.

Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes.

Domenica Rubino discusses the chronicity of obesity, and how STEP 4 demonstrates the need for long-term semaglutide treatment to avoid weight regain (5:59).

Ildiko Lingvay discusses the STEP 2 findings, and why a higher semaglutide dose may be optimal for most people with type 2 diabetes (8:06).

Thomas Wadden explains the rationale behind STEP 3 trial, and why semaglutide is the “breakthrough people with overweight and obesity have been waiting for.” (7:41)

Lead author of the STEP 1 trial, John Wilding, discusses the findings and what they may mean for the treatment of people with obesity (5:42)

Chantal Mathieu comments on why research into psychosocial care is important for people with type 2 diabetes, focusing on the burden of treatment for those requiring insulin and the association between some glucose-lowering drugs and weight gain.

David Maahs outlines the impact of psychosocial factors on children with diabetes and their families, and explains how psychosocial research can help build the tools to alleviate disease burden.

Irl Hirsch talks about the challenges presented by psychosocial problems related directly and indirectly to having type 1 diabetes.

Francesco Giorgino comments on the findings from the VERTIS-CV trial, and discusses the cardiovascular efficacy and safety of ertugliflozin in the context of the SGLT2 inhibitor class (10:10).

Lead investigator Chris Cannon discusses the VERTIS-CV trial, showing that the SGLT2 inhibitor ertugliflozin is noninferior to placebo for the prevention of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (7:16).

Matthew Crowley discusses the successful implementation of a telehealth service for rural people with type 2 diabetes in clinical practice and its relevance to the current pandemic (13:07).

Jay Shubrook comments on a subgroup analysis of the REDUCE-IT trial demonstrating that icosapent ethyl reduces the risk for cardiovascular events in statin-treated patients with diabetes (3:39).

Mikhail Kosiborod outlines the findings from the DEFINE-HF trial, and discusses the possible reasons why dapagliflozin had an impact on one primary endpoint but not the other (5:48).

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08).

Athena Philis-Tsimikas discusses which patients may benefit the most from treatment with long-acting insulins, and how the data from CONCLUDE compare with real-world study findings (2:38).